Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Soros to Buy $40 Million of Sihuan Pharma’s Hong Kong IPO

publication date: Oct 14, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
According to press reports, George Soros, the billionaire international investor, has committed $40 million to Sihuan Pharma’s upcoming Hong Kong IPO, one of six cornerstone investors in the offering. Sihuan, China’s largest cardio-cerebral vascular drugmaker, plans to raise $749 million in its IPO. More details....

Stock Symbol: (HK: 0460)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



ChinaBio® Events
Suzhou, China
May 18 - 19, 2016
Record attendance of 1008!
See us next year in Shunde!

>> More events...

Other Events
Hong Kong, China
June 15–17, 2016
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors